{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:24:02Z","timestamp":1780377842495,"version":"3.54.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009540","name":"Frank A. Campini Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Pediatric diseases treated by allogeneic hematopoietic stem cell transplantation (alloHCT) are complex and associated with significant comorbidities and medication requirements that can complicate the transplant process. It is critical to reconcile pre-transplant concomitant medications (pcon-meds) in the weeks prior to alloHCT and to consider the potential for pcon-meds to cause harmful drug-drug interactions (DDIs) or overlapping toxicities with conditioning agents. In this perspective, we describe a systematic process to review pcon-meds and determine the drug modifications needed to avoid DDIs with conditioning regimens. We provide an extensive appendix with timelines for discontinuation or modification of common pcon-meds that patients are taking when presenting to the HCT medical team. The timelines are based on the pharmacokinetic (PK) properties of both the pcon-meds and the planned conditioning medications, as well as anticipated DDIs. They also account for the ages seen at pediatric transplant centers (0\u201330 years old). Common scenarios, such as when pcon-med discontinuation is not an option, are discussed. Since alloHCT patients are often dependent upon psychiatric medications with problematic DDIs, a table of alternative, non-interacting psychiatric medications is also presented. The appendix provides details regarding how to adjust pcon-meds prior to the start of chemotherapy for children and young adults undergoing alloHCT, however patient-specific circumstances always need to be taken into account. Careful attentiveness to pcon-meds at the time the decision is made to pursue transplant will result in more consistent HCT outcomes, with lower toxicity and increased efficacy of conditioning agents.<\/jats:p>","DOI":"10.3389\/fped.2021.713091","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T06:07:20Z","timestamp":1626674840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults"],"prefix":"10.3389","volume":"9","author":[{"given":"Beth","family":"Apsel Winger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie E.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish O.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Dvorak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janel Renee","family":"Long-Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5152\/tpa.2014.2010","article-title":"Hematopoetic stem cell transplantation in children","volume":"49","author":"Yesilipek","year":"2014","journal-title":"Turk Pediatri Ars."},{"key":"B2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bbmt.2011.11.029","article-title":"Important drug interactions in hematopoietic stem cell transplantation: what every physician should know","volume":"18","author":"Glotzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1704316","article-title":"Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know","volume":"33","author":"Leather","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"B4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/10837450902891550","article-title":"Drug interactions","volume":"41","author":"Boobis","year":"2009","journal-title":"Drug Metab Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr Drug Targets."},{"key":"B6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jps.2600750302","article-title":"Kinetic models of induction: I. Persistence of the inducing substance","volume":"75","author":"Abramson","year":"1986","journal-title":"J Pharm Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0076-6879(91)06101-8","article-title":"Cytochrome P450 turnover","volume":"206","author":"Correia","year":"1991","journal-title":"Methods Enzymol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1586\/ecp.11.30","article-title":"Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs","volume":"4","author":"Imai","year":"2011","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0897190012467210","article-title":"Guidance for the discontinuation or switching of antidepressant therapies in adults","volume":"26","author":"Ogle","year":"2013","journal-title":"J Pharm Pract."},{"key":"B12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.mph.0000155870.38794.e7","article-title":"Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase","volume":"27","author":"Saracco","year":"2005","journal-title":"J Pediatr Hematol Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/IDR.S12714","article-title":"Update on the optimal use of voriconazole for invasive fungal infections","volume":"4","author":"Lat","year":"2011","journal-title":"Infect Drug Resist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.bbmt.2007.03.005","article-title":"Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation","volume":"13","author":"Upton","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00280-016-3153-0","article-title":"Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients","volume":"78","author":"Forster","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1139\/y02-070","article-title":"Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study","volume":"80","author":"Diserbo","year":"2002","journal-title":"Can J Physiol Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.brainres.2011.11.022","article-title":"Radiation-induced blood-brain barrier damages: an in vitro study","volume":"1433","author":"Fauquette","year":"2012","journal-title":"Brain Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","article-title":"Veno-occlusive disease of the liver after hemopoietic cell transplantation","volume":"64","author":"Carreras","year":"2000","journal-title":"Eur J Haematol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.713091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T06:07:22Z","timestamp":1626674842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.713091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":21,"alternative-id":["10.3389\/fped.2021.713091"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.713091","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"article-number":"713091"}}